ATE65392T1 - In mizellulare phospholipidische partikel eingekapselte antineoplastische anthracyclinmittel. - Google Patents

In mizellulare phospholipidische partikel eingekapselte antineoplastische anthracyclinmittel.

Info

Publication number
ATE65392T1
ATE65392T1 AT86301513T AT86301513T ATE65392T1 AT E65392 T1 ATE65392 T1 AT E65392T1 AT 86301513 T AT86301513 T AT 86301513T AT 86301513 T AT86301513 T AT 86301513T AT E65392 T1 ATE65392 T1 AT E65392T1
Authority
AT
Austria
Prior art keywords
particles
micellular
phospholipidic
antineoplastic agents
anthracycline
Prior art date
Application number
AT86301513T
Other languages
English (en)
Inventor
Eric Forssen
Original Assignee
Vestar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25141806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE65392(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vestar Inc filed Critical Vestar Inc
Application granted granted Critical
Publication of ATE65392T1 publication Critical patent/ATE65392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT86301513T 1985-10-15 1986-03-04 In mizellulare phospholipidische partikel eingekapselte antineoplastische anthracyclinmittel. ATE65392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78753585A 1985-10-15 1985-10-15
EP86301513A EP0219922B2 (de) 1985-10-15 1986-03-04 In mizellulare phospholipidische Partikel eingekapselte antineoplastische Anthracyclinmittel

Publications (1)

Publication Number Publication Date
ATE65392T1 true ATE65392T1 (de) 1991-08-15

Family

ID=25141806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86301513T ATE65392T1 (de) 1985-10-15 1986-03-04 In mizellulare phospholipidische partikel eingekapselte antineoplastische anthracyclinmittel.

Country Status (10)

Country Link
US (1) US4769250A (de)
EP (1) EP0219922B2 (de)
JP (1) JPH0761947B2 (de)
KR (1) KR890004689B1 (de)
AT (1) ATE65392T1 (de)
AU (1) AU587232B2 (de)
DE (1) DE3680447D1 (de)
DK (1) DK175201B1 (de)
IE (1) IE58981B1 (de)
NO (1) NO172729C (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5435989A (en) * 1982-03-30 1995-07-25 Vestar, Inc. Method of targeting a specific location in a body
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US4863739A (en) * 1987-05-19 1989-09-05 Board Of Regents, The University Of Texas System Liposome compositions of anthracycline derivatives
JP2501336B2 (ja) * 1987-07-02 1996-05-29 第一製薬株式会社 安定なリポソ−ム製剤
FI874742A (fi) * 1987-10-28 1989-04-29 K & V Licencing Oy Foerfarande foer framstaellning av liposomer.
IE63518B1 (en) * 1987-11-18 1995-05-03 Vestar Inc Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
US4946683A (en) * 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
JPH03502327A (ja) * 1988-01-19 1991-05-30 ボード・オブ・リージェンツ，ザ・ユニバーシティ・オブ・テキサス・システム ３’‐デアミノドキソルビシンのエステル体、そのリポソーム組成物およびその使用方法
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
WO1990003795A1 (en) * 1988-10-05 1990-04-19 Vestar, Inc. Method of making liposomes with improved stability during drying
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20010051183A1 (en) * 1989-10-20 2001-12-13 Alza Corporation Liposomes with enhanced circulation time and method of treatment
US6060080A (en) * 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
CA2046997C (en) * 1990-07-16 2000-12-12 Hiroshi Kikuchi Liposomal products
DE4023241A1 (de) * 1990-07-21 1992-01-23 Knoll Ag Stabile wirkstoff-formulierung
ATE138803T1 (de) * 1990-07-31 1996-06-15 Liposome Co Inc Anhäufung von aminosäuren und peptiden in liposomen
JP2599492B2 (ja) * 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
DE69113640T2 (de) * 1991-07-03 1996-03-07 Vestar Inc Beladungstechnik zur herstellung arzneistoffhaltiger liposomen.
US5665381A (en) * 1992-02-25 1997-09-09 Nexstar Pharmaceuticals, Inc. Inhibition of aggregation of drug containing particles
BR9201168A (pt) * 1992-04-02 1994-04-12 Zerbini E J Fundacao Microemulsoes usadas como velculo para carregar quimioterapicos as celulas neoplasicas
WO1994008564A1 (en) * 1992-10-08 1994-04-28 Valery Yu Alakhov Composition of antineoplastic agents incorporated in micelles
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US5455044A (en) * 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
CA2176712C (en) * 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
EP0664117A1 (de) * 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposomenlösungen
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US20040208922A1 (en) * 1995-06-07 2004-10-21 The Regents Of The University Of California Method for loading lipid like vesicles with drugs or other chemicals
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2254772C (en) * 1996-05-14 2004-01-27 Stanislaw R. Burzynski Liposomal antineoplaston therapies with markedly improved antineoplastic activity
US6060518A (en) * 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
DE19639811A1 (de) * 1996-09-27 1998-04-02 Artur Herzog Dr Mesmer Verwendung einer Liposomenlösung zur Verstärkung der Wirksamkeit und/oder Verminderung der Toxizität von Arzneimitteln
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1999002139A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6306432B1 (en) 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
AU735588B2 (en) * 1997-09-18 2001-07-12 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
JP4575592B2 (ja) 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
AU5246900A (en) * 1999-06-14 2001-01-02 Japan Science And Technology Corporation Anticancer emulsions containing anthracycline compounds
CA2449856C (en) * 2001-06-15 2009-03-10 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
MXPA04002847A (es) * 2001-09-28 2004-07-05 Esperion Therapeutics Inc Metodo y aparato para la extrusion de vesiculas a presion alta.
PT1443900E (pt) * 2001-11-13 2012-08-01 Celator Pharmaceuticals Inc Composições de veículo lipídico com estabilidade melhorada no sangue
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
GB2398495B (en) * 2003-01-23 2007-08-22 Kent G Lau A drug delivery preparation comprising at least one anti-tumour drug and a topical carrier for the drug
WO2007070705A2 (en) * 2005-12-15 2007-06-21 The Trustees Of The University Of Pennsylvania Cationic lipid-mediated vectors
CN105147594A (zh) * 2007-11-30 2015-12-16 恩德制药解决方案公司 用于治疗膀胱癌的含戊柔比星的膀胱内剂型组合物
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
CH621479A5 (de) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
US4310505A (en) * 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
JPS5793909A (en) * 1980-12-03 1982-06-11 Sankyo Co Ltd Carcinostatic pharmaceutical having directivity to specific internal organ and its preparation
US4419348A (en) * 1981-04-27 1983-12-06 Georgetown University Anthracycline glycoside compositions, their use and preparation
US4427664A (en) * 1981-05-29 1984-01-24 The United States Of America As Represented By The Department Of Health And Human Services 2'Halo derivatives of daunomycin, desmethoxy daunomycin, adriamycin and carminomycin
CA1187434A (en) * 1981-08-11 1985-05-21 Akihiro Yoshimoto Anthracycline antibiotics and their preparation method
EP0088046B1 (de) * 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4438105A (en) * 1982-04-19 1984-03-20 Farmaitalia Carlo Erba S.P.A 4'-Iododerivatives of anthracycline glycosides
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
WO1985000968A1 (en) * 1983-09-06 1985-03-14 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
IL69720A (en) * 1983-09-14 1987-08-31 Univ Ramot Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins

Also Published As

Publication number Publication date
AU5418486A (en) 1987-04-16
EP0219922A3 (en) 1987-10-28
NO172729C (no) 1993-09-01
AU587232B2 (en) 1989-08-10
JPH0761947B2 (ja) 1995-07-05
EP0219922B2 (de) 2002-08-28
DK175201B1 (da) 2004-07-05
EP0219922B1 (de) 1991-07-24
NO172729B (no) 1993-05-24
DK98886A (da) 1987-04-16
KR870003775A (ko) 1987-05-04
IE58981B1 (en) 1993-12-15
NO862193L (no) 1987-04-21
KR890004689B1 (ko) 1989-11-25
US4769250A (en) 1988-09-06
JPS6287514A (ja) 1987-04-22
IE860535L (en) 1987-04-15
DK98886D0 (da) 1986-03-04
DE3680447D1 (de) 1991-08-29
NO862193D0 (no) 1986-06-03
EP0219922A2 (de) 1987-04-29

Similar Documents

Publication Publication Date Title
ATE65392T1 (de) In mizellulare phospholipidische partikel eingekapselte antineoplastische anthracyclinmittel.
NO873492L (no) Fremgangsmaate for fremstilling av antifungale preparater.
DK433484A (da) Medikamentholdigt lipidvesikelpraeparat
NL300036I1 (nl) Liposomale formuleringen met een hoge anti-neoplastisch middel/lipideverhouding.
DK86988A (da) Liposompraeparat og anvendelse deraf
AR241117A2 (es) Procedimiento para la preparacion de complejos de flavanolignanos con fosfolipidos
KR950700725A (ko) 리포솜 조성물(liposome composition)
DK32388A (da) Phospholipid-baeremiddel for vand-uoploeselige aktive bestanddele
HUP0104665A2 (hu) Proantocianidin A2 foszfolipid-komplexek mint antiatheroszklerotikus ágensek
DE3878922D1 (de) Mehrstufen-einkapselungs/ladeverfahren zur herstellung von lipophile heilmittel enthaltenden liposomen.
DK484685A (da) Micellulaere partikelkompositioner til maalrettet tilfoersel til tumorer i mennesker og kompositionernes anvendelse
DE69005173D1 (de) Heilungsfördernde Zusammensetzung.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0219922

Country of ref document: EP

EELA Cancelled due to lapse of time